Intervju Following a year of significant transformation, Hansa Biopharma is preparing for what could become the company's most important commercial phase to date. With a strengthened financial position, positive Phase 3 results and a potential US approval of imlifidase on the horizon, CEO Renée Aguiar-Lucander discusses the company's strategy, upcoming catalysts and why she believes Hansa is entering a new era of long-term value creation.
Where are you right now and what do the next few years look like?
– We are at a pivotal stage in Hansa Biopharma’s development. During the past year I believe that we have fundamentally transformed Hansa. We have rightsized the organisation, addressed the capital structure and generated positive Phase 3 and European confirmatory data that supports the potential of imlifidase for highly sensitized patients awaiting a kidney transplantation. We have also significantly strengthened our financial position recently through our European out-licensing agreement with SERB Pharmaceuticals.
Looking ahead, our primary focus is on addressing the significant unmet medical need in the US market, subject to regulatory approval, while continuing to advance late stage trials with our second product candidate and leverage our innovative platform. Following a potential approval and commercialisation in the US, we will also consider potential in-licensing of complementary late stage or commercial assets. We believe we are entering a period where years of scientific investment can begin translating into broader patient impact and long-term value creation.
What has, in the near future, affected or is affecting the company’s position the most?
– The most significant development has been attracting and building of a strong and experienced senior team, able to navigate the various aspects of the complex biotech environment, including successfully launching rare products in the US market. Furthermore, the transaction with SERB Pharmaceuticals has strengthened our balance sheet, streamlined our operational focus, and provided greater flexibility to invest in our US commercialization plans and long-term growth strategy.
We are, as all biotech companies, dependent on clinical results and regulatory agency decisions. In the near term the most important catalyst for Hansa is the outcome of the FDA’s review of the BLA for imlifidase in the US. Subject to regulatory approval, we believe the US market represents a significant opportunity to expand patient access to our therapy and further accelerate the development of the company.
At the same time, the continued generation of positive clinical data is critical. The encouraging results from both the Phase 3 ConfIdeS study and the European post-authorization study reinforce the scientific foundation for our approach and increase confidence in the potential of imlifidase to address a serious unmet medical need.
What are your biggest challenges?
– As with any biotechnology company, success in our industry demands vision, scientific excellence, agility and disciplined execution. Bringing innovative therapies to patients requires navigating complex regulatory processes, generating robust clinical evidence, and ensuring appropriate access within healthcare systems.
I believe that Hansa is well positioned to take on and conquer any challenges it might face. The immediate challenge, or opportunity, is to ensure a successful outcome of our regulatory review process. Subsequently, we obviously have to deliver on the execution, however I think that we are well prepared and ready. We have created strong momentum, and our responsibility is now to deliver on that opportunity, whether through regulatory progress, commercial readiness, or continued scientific advancement. We remain focused on maintaining a balance between ambition and operational excellence.
Tell us a little about your vision. Where are you headed?
– Our vision is simple: Through pioneering science and collaboration we enable life changing outcomes for patients with acute or serious immune mediated conditions.
We have already demonstrated how our antibody-cleaving technology can enable transplantation for highly sensitized patients on the kidney waitlist who otherwise have very limited treatment options. Looking ahead, we aim to build a sustainable, US focused, biotechnology company that combines scientific leadership with commercial execution. We want to continue advancing innovation, expanding the impact of our technology, and creating meaningful value for patients, healthcare systems, and shareholders alike.
What can a shareholder expect from you as a company?
– Shareholders can expect a company that remains true to its values and is focused on disciplined execution, scientific rigor, and long-term value creation. We pride ourselves on being a pioneer, bringing transparency to issues and solving problems with agility and integrity. We are committed to leverage the collective experience of our staff and to invest in a culture that is forward leaning, takes responsibility and is solutions oriented.
Our strategy is grounded in creating meaningful outcomes for patients while building a financially sustainable business. We will continue to make considered and appropriate decisions that strengthen our ability to execute on our priorities, invest where we see the greatest potential, and maintain a clear focus on delivering milestones that support our long-term growth ambitions.
Most importantly, shareholders can expect transparency, a high-performance culture, and an unwavering commitment to turning scientific innovation into real-world impact.
To learn more about Hansa Biopharma, please visit the company's official website
Det här är en sponsrad artikel framtagen i samarbete med Hansa Biopharma. Sponsrade inlägg är en del av Börsvärldens annonserbjudande. Om du med anledning av våra sponsrade inlägg önskar att komma i kontakt med oss, vänligen skriv till IR@borsvarlden.com.
LÄS MER
